Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juni 2022

Genmab — Juni 2022

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #26

    Ingen tvivl om,at der skeles mere og mere til P/E, når der handles i Genmab. Men der er stadig god grund til at handle i den høje ende med en forventet stor vækst og med eks. epcoritamab nærmere markedsføring.

    1 Reply Last reply
    0
    • D Offline
      D Offline
      deleted-user
      wrote on sidst redigeret af
      #27

      @Gasolin82 - Roche som er et modent selskab bruger ca. 20-25 % af indtægterne på RD. Genmab ligger lang tidligere i den cyklus, hvilket også afspejles i RD udgør 50 % af indtægterne. Blot for at have et pejlemærke.

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #28

        USA/åbning: Solstrejf efter overskyet tirsdag
        https://www.proinvestor.com/investornyt/831814/usa-abning-solstrejf-efter-overskyet-tirsdag

        1 Reply Last reply
        0
        • P Offline
          P Offline
          ProinvestorNEWS
          wrote on sidst redigeret af
          #29

          Onsdagens aktier: Mærsk til tops i usikkert, negativt marked
          https://www.proinvestor.com/investornyt/831888/onsdagens-aktier-maersk-til-tops-i-usikkert-negativt-marked

          1 Reply Last reply
          0
          • P Offline
            P Offline
            ProinvestorNEWS
            wrote on sidst redigeret af
            #30

            Major Shareholder Announcement https://www.proinvestor.com/investornyt/831947/major-shareholder-announcement

            1 Reply Last reply
            0
            • P Offline
              P Offline
              ProinvestorNEWS
              wrote on sidst redigeret af
              #31

              Den nye aktionær med over 5%: https://www.wellington.com/en/

              1 Reply Last reply
              0
              • MadsSkjernM Offline
                MadsSkjernM Offline
                MadsSkjern
                wrote on sidst redigeret af
                #32

                Abbvie om epco https://twitter.com/bertrandbio/status/1532017882573459459?s=21&t=189vAgnCO369-t3SHoVu8g

                1 Reply Last reply
                0
                • MadsSkjernM Offline
                  MadsSkjernM Offline
                  MadsSkjern
                  wrote on sidst redigeret af
                  #33

                  JnJ om darzalex: it’s gonna be our largest drug https://twitter.com/bertrandbio/status/1532009827899260931?s=21&t=189vAgnCO369-t3SHoVu8g

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #34

                    Hov, så må tallet - kongetallet om noget - være sivet. Ca 40% CR!

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #35

                      Major Shareholder Announcement Wellington Management Group LLP has informed us that, as of May 27, 2022, Wellington Management Group LLP through shares and financial instruments holds the voting rights 5.01% of the share capital and voting rights in Genmab A/S. https://www.globenewswire.com/news-release/2022/06/01/2454605/0/en/Major-Shareholder-Announcement.html

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #36

                        Som de siger: Bedst i alle parametre.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #37

                          Tak Mads

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #38

                            we did not have that CR yet, did we?

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #39

                              No it looks like abbvie has said it in an interview with bernstein

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #40

                                Maybe it’s official tomorrow together with eha lba.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #41

                                  excellent. so my guess is we are looking at roughly CR45% for patients that did not have CAR/T yet

                                  1 Reply Last reply
                                  0
                                  • BulderB Offline
                                    BulderB Offline
                                    Bulder
                                    wrote on sidst redigeret af
                                    #42

                                    Yes if 40% is avg of car-t and non car-t.

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #43

                                      If this is true, it’s outstanding.

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #44

                                        In the escalation part CR was 38%.

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #45

                                          Johnson & Johnson (JNJ) CEO Joaquin Duato Presents at Bernstein 38th Annual Strategic Decisions Conference https://seekingalpha.com/article/4515795-johnson-and-johnson-jnj-ceo-joaquin-duato-presents-bernstein-38th-annual-strategic-decisions

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper